Medical Oncologist
CION Cancer Clinics
Why every biliary cancer should be molecularly tested | CION Cancer Clinics
Every bile duct cancer that may need medicines should have its tumour DNA tested, because some carry changes such as FGFR2 fusions or IDH1 mutations that specific medicines can target. You cannot tell from a scan or a biopsy report alone. This page explains what the test looks for, how it is done, what the report words mean and who it does not help. At CION Cancer Clinics in Hyderabad, our oncologists explain liver cancer in plain words and plan care around you and your family.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed October 2026, next review due October 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Why should a bile duct cancer have molecular testing?
- What does the test look for in cholangiocarcinoma?
- How does molecular testing happen?
- What do the words on a molecular report mean?
- What do families often misunderstand about this test?
- Who does this not suit, and what can this page not tell you?
- Common questions about molecular testing
The short answer
Why should a bile duct cancer have molecular testing?
Because a meaningful share of bile duct cancers carry a change in their DNA that a specific medicine can target. You only find out by testing the tumour. Changes such as FGFR2 fusions and IDH1 mutations are among the most common in cholangiocarcinoma that starts inside the liver.
What molecular testing actually is
A laboratory reads the DNA, and sometimes the RNA, of cancer cells taken from a biopsy or an operation. It looks for faults that drive the cancer's growth. This is often called molecular profiling, genomic testing or NGS, which stands for next-generation sequencing. It is a test of the tumour, not of you or your family.
Why it matters now, not later
Most people with this cancer start with chemotherapy, often combined with immunotherapy. If the cancer grows again, the next choice depends on the test result. Waiting until then can mean a new biopsy and lost time, so many oncologists ask for testing as soon as the diagnosis is confirmed. Our page on staging intrahepatic cholangiocarcinoma explains where testing fits.
Testing opens a door for some people. It does not promise that a matched medicine will exist, or work, for everyone.The changes that matter
What does the test look for in cholangiocarcinoma?
Each of these changes is found in only some tumours. A single panel test checks for all of them at once.
FGFR2 fusions
Part of the FGFR2 gene has joined onto another gene, switching on a growth signal. Medicines called FGFR inhibitors, such as pemigatinib and futibatinib, were developed for this. Read more on FGFR2 fusions.
IDH1 mutations
A fault in IDH1 makes cells produce a substance that blocks normal development. Ivosidenib targets it. Our page on IDH1 mutations covers this in detail.
HER2, BRAF and NTRK
Less common changes, each with medicines studied against them.
- HER2 amplification
- BRAF V600E mutation
- NTRK gene fusions
MSI-high and tumour mutational burden
These describe a tumour with many DNA errors. They are uncommon in bile duct cancer, but when present they can make immunotherapy more likely to help.
Not sure whether this applies to you?
Ask an oncologistFrom sample to result
How does molecular testing happen?
Your oncologist requests it
The request names the test panel and the sample to use. It is worth asking at the first consultation whether testing has been sent.
The tissue is found and checked
The pathologist looks for the stored block from your biopsy or operation and checks there are enough cancer cells. Bile duct biopsies are often small, which is the most common reason a test fails.
A blood test if tissue runs short
A liquid biopsy reads tumour DNA shed into the blood. It can help when tissue is too scant, though it can miss fusions such as FGFR2 that a tissue test would catch.
The laboratory reads the DNA
Results usually take a few weeks. CION coordinates testing through accredited diagnostic partners, and the cost is quoted separately because it varies by laboratory and panel.
The tumour board reviews the report
The report lists every change found. The team decides which ones matter for treatment and which are simply noted.
On your report
What do the words on a molecular report mean?
- Actionable
- A change for which a medicine exists or is being studied. It does not mean the medicine is available, approved or right for you.
- Fusion
- Two genes that have broken and joined together, sending a constant growth signal. FGFR2 fusions are the best known in this cancer.
- Variant of uncertain significance
- A change the laboratory cannot yet interpret. It should not guide treatment on its own.
- Somatic
- Found only in the tumour. It was not inherited and cannot be passed to children. Most findings on this test are somatic.
- Germline
- Present in every cell from birth. If a tumour test hints at one, your doctor may suggest a separate blood test and a talk with a genetic counsellor.
- No actionable change found
- A common result. It means treatment follows the standard plan, not that the test was wasted.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Commonly believed
What do families often misunderstand about this test?
"If they find a mutation, there is a tablet that will fix it."
A matched medicine can control the cancer for a time in some people. It does not remove the cancer, and it does not suit everyone with that change. Some of these medicines are not approved in India and reach patients only through import or clinical trials.
"This test shows whether my children will get cancer."
It tests the tumour, not the family. Most changes it finds started in the cancer itself and cannot be inherited. A separate test answers the family question when it is needed.
"Testing will delay starting treatment."
First treatment usually starts while the result is awaited. The result shapes the next step, which is why sending the test early saves time rather than losing it.
"A second biopsy will make the cancer spread."
This is a common worry, and the evidence does not support it for planned biopsies. Our page on the biopsy spreading cancer myth explains why.
Being straight with you
Who does this not suit, and what can this page not tell you?
Testing helps least for someone too unwell for any further cancer medicine, because a result would not change what is offered. It also matters less for hepatocellular carcinoma, where matched medicines are still rare. Our page on molecular profiling in liver cancer covers that separately.
It cannot read your report for you
The same gene name can mean different things depending on the exact change and how the laboratory classifies it. Bring the full report to your oncologist rather than searching each gene online.
It cannot promise a medicine
Whether a matched medicine is available in India, affordable and suitable depends on your liver function, your fitness and what has been tried already. The mechanics and side effects of these medicines are explained on our page on targeted therapy for bile duct cancer.
If you are unsure whether testing was ever sent, ask your current team. A stored biopsy block can often still be tested.Questions we are asked
Common questions about molecular testing
Does every bile duct cancer need molecular testing?
International guidance recommends it for advanced or recurrent bile duct cancer, and many oncologists ask for it at diagnosis. It applies to cancers inside the liver, around the hilum and further down the duct. Your oncologist will decide the timing based on your stage and fitness.
What is the difference between FGFR2 and IDH1?
They are two different faults, each driving growth in its own way, and each has its own medicine. A tumour usually has one or the other, not both. Both are found more often in cholangiocarcinoma that starts inside the liver than in cancer further down the bile duct.
Can the test be done on an old biopsy?
Often, yes. Biopsy and surgery samples are stored as wax blocks and can be tested later. The pathologist checks whether enough cancer cells remain. If the old sample is too small, a fresh biopsy or a blood-based test may be suggested instead.
Is a blood test as good as a tissue test?
Not quite. A liquid biopsy is useful when tissue is scarce, and a positive result is meaningful. A negative result is less reliable, because the blood may not carry enough tumour DNA, and some fusions are easily missed. Tissue remains the first choice where possible.
Are FGFR and IDH1 medicines available in India?
Availability changes and differs by medicine. Some are not approved in India and are obtained through import or clinical trials, which affects cost and timing. Ask your oncologist for the current position before relying on any one option, and ask for a written estimate.
Does this test cost a lot?
It is one of the more costly tests in cancer care, and the price varies by laboratory and by how many genes the panel covers. Insurance and government schemes treat it differently, and their rules change. Ask for an itemised quote and check cover before the sample is sent.
If nothing is found, was the test pointless?
No. A clear result tells your team that standard treatment is the right path, and it avoids chasing a medicine that would not help. Some reports also note changes that may matter for a clinical trial later, so keep a copy safely.
How do I ask CION about testing?
Call the CION helpline with your biopsy report and the name of the hospital that holds the tissue block. Someone will arrange a consultation, check whether testing has been done and explain how a sample can be sent to an accredited laboratory.
Your Specialists
Meet CION's liver cancer specialists. Bring your scan reports and liver blood tests.
Our medical and surgical oncologists plan liver cancer care together, weighing the tumour and how well your liver works before choosing surgery, a liver-directed procedure or medicines.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — Bile Duct Cancer Targeted Therapy
- American Cancer Society — Bile Duct Cancer Immunotherapy
- National Cancer Institute — Bile Duct Cancer Treatment
- Cholangiocarcinoma Foundation — Resources & Support for Bile Duct Cancer
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
FGFR2 fusions in bile duct cancerThe most studied target, explained on its ownIDH1 mutations in bile duct cancerThe second common target and its medicineHER2, BRAF and MSI in bile duct cancerThe less common changes a panel can findTargeted therapy for bile duct cancerHow the matched medicines work and their side effects
Talk to us
Not sure whether the tumour was ever tested?
Send us the biopsy report and we will check whether molecular testing was done and how a stored sample can be tested if not. One helpline serves every CION centre.